Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–14.

Article  PubMed  CAS  Google Scholar 

Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, He AL, Mi JQ, Chen SJ. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17(1):23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol 2023, 16(1):92.

Liu X, Zhao J, Guo X, Song Y. CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023;16(1):90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Huang X. In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy. J Hematol Oncol. 2024;17(1):110.

Article  PubMed  PubMed Central  Google Scholar 

Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16.

Article  PubMed  PubMed Central  Google Scholar 

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482–94.

Article  PubMed  CAS  Google Scholar 

Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Simkovic M, Shadman M, Osterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trneny M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–43.

Article  PubMed  CAS  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-Engineering for Modulated Effector functions-improving antibodies for Cancer Treatment. Antibodies (Basel) 2020, 9(4).

Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Harnessing the immune system via FcgammaR function in immune therapy: a pathway to next-gen mAbs. Immunol Cell Biol. 2020;98(4):287–304.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal antibodies. Cancer Res. 2021;81(18):4641–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789–805.

Article  PubMed  CAS  Google Scholar 

Bournazos S, Gupta A, Ravetch JV. The role of IgG fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633–43.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mysore V, Cullere X, Mears J, Rosetti F, Okubo K, Liew PX, Zhang F, Madera-Salcedo I, Rosenbauer F, Stone RM, Aster JC, von Andrian UH, Lichtman AH, Raychaudhuri S, Mayadas TN. FcgammaR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. Nat Commun. 2021;12(1):4791.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Macri C, Morgan H, Villadangos JA, Mintern JD. Regulation of dendritic cell function by Fc-gamma-receptors and the neonatal fc receptor. Mol Immunol. 2021;139:193–201.

Article  PubMed  CAS  Google Scholar 

Forest-Nault C, Gaudreault J, Henry O, Durocher Y, De Crescenzo G. On the Use of Surface Plasmon Resonance Biosensing to understand IgG-FcgammaR interactions. Int J Mol Sci 2021, 22(12).

Wang TT, Ravetch JV. Functional diversification of IgGs through fc glycosylation. J Clin Invest. 2019;129(9):3492–8.

Article  PubMed  PubMed Central  Google Scholar 

Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc/FcgammaR complexes: a blueprint for antibody design. Immunol Rev. 2015;268(1):201–21.

Article  PubMed  CAS  Google Scholar 

Dahal LN, Roghanian A, Beers SA, Cragg MS. FcgammaR requirements leading to successful immunotherapy. Immunol Rev. 2015;268(1):104–22.

Article  PubMed  CAS  Google Scholar 

Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity fc gamma R genes: duplication and recombination. Science. 1990;248(4956):732–5.

Article  PubMed  CAS  Google Scholar 

Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med. 1989;170(4):1369–85.

Article  PubMed  CAS  Google Scholar 

Lu H, Molony RD, Chen D, Jang S, Wolf B, Ewert S, Flaherty M, Xu F, Isim S, Shim Y, Dornelas C, Balke N, Leber XC, Scharenberg M, Koelln J, Choi E, Ward R, Johnson J, Calzascia T, Isnardi I, Williams JA, Lindenbergh PL, van de Donk N, Mutis T, Huet H, Lees E, Meyer MJ. Development of Anti-CD32b antibodies with enhanced fc function for the treatment of B and plasma cell malignancies. Mol Cancer Ther. 2020;19(10):2089–104.

Article  PubMed  CAS  Google Scholar 

Hargreaves CE, Rose-Zerilli MJ, Machado LR, Iriyama C, Hollox EJ, Cragg MS, Strefford JC. Fcgamma receptors: genetic variation, function, and disease. Immunol Rev. 2015;268(1):6–24.

Article  PubMed  CAS  Google Scholar 

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–8.

Article  PubMed  CAS  Google Scholar 

Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to Rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940–7.

Article  PubMed  CAS  Google Scholar 

Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Juttner M, Ehlert K, Kietz S, Muller I, Lode HN. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncoimmunology. 2016;5(11):e1235108.

Article  PubMed  PubMed Central  Google Scholar 

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O’Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018;7(11):5478–87.

Article  PubMed  PubMed Central